Servier India launches IDH1-targeted therapy Ivosidenib for AML and Cholangiocarcinoma EP News Bureau Jun 5, 2025 CDSCO approves Servier’s Ivosidenib for treatment of AML and Cholangiocarcinoma patients with IDH1 mutation
CDSCO issues compliance framework for SEZ-to-DTA drug transfers Neha Aathavale Apr 11, 2025 New circular standardises licensing pathway for domestic diversion of SEZ-manufactured drugs; however system-level changes raise…
